Drugs / extra virgin olive oil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03362996 | Nov 2016 → Feb 2018 | cognitive impairment with or without cerebellar ataxia | Greek Alzheimer's Association and Related Disorders | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | extra virgin olive oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03362996 ↗ |
| Known as | EVOO | “The daily consumption of Extra Virgin Olive Oil (EVOO) in Mediterranean nutrition is tightly associated with lower frequency of many diseases' appearance, including Alzheimer's...” PMID 33836262 ↗ Apr 2021 |
| Route | Oral | “Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)” NCT03362996 ↗ |